Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early treat-to-target control in rheumatoid arthritis: tofacitinib plus methotrexate versus conventional DMARDs plus methotrexate
ChiCTR2000033214Phase 4Not yet recruiting
- Sponsor
- Department of Rheumatology, Anqing Hospital Affiliated to Anhui Medical University
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tofacitinib and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Department of Rheumatology, Anqing Hospital Affiliated to Anhui Medical University. Primary endpoints: Visual Analog Scale, Health Assessment Questionnaire and 1 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
tofacitinibmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2000033214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033214.